2025 PACUPrep BCCCP Preparatory Course Hepatic Encephalopathy Recovery, De‐escalation, and Transition of Care in Hepatic Encephalopathy
Recovery and Transition of Care in Hepatic Encephalopathy

Recovery, De-escalation, and Transition of Care in Hepatic Encephalopathy

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Learning Objective

  • Establish structured protocols for weaning ammonia-lowering therapies, converting to enteral/oral regimens, mitigating post-ICU sequelae, and ensuring safe discharge with outpatient follow-up.

1. Weaning and De-escalation of Ammonia-Lowering Therapies

As mental status stabilizes and precipitating factors are controlled, gradual tapering of lactulose and adjustment of adjuncts minimizes rebound hyperammonemia and gastrointestinal side effects.

Protocol for Tapering Lactulose

  • Prerequisite: At least 72 hours of stable mental status (West Haven Grade 0–I) and resolved precipitants.
  • Target: Maintain 2–3 soft stools per day. Avoid excessive catharsis which can lead to dehydration and electrolyte imbalances.
  • Taper Steps: Reduce the total daily dose by 10–20% every 3–5 days. Ensure remaining doses are split evenly throughout the day.
  • Daily Monitoring: Closely track stool frequency and consistency, mental status, and volume/electrolyte status.
  • Contingency: If stool count falls below 2 per day or signs of hepatic encephalopathy (HE) recur, revert to the previous effective dose and reassess the patient’s clinical status.

Adjunctive Therapy Adjustment: Rifaximin

  • Continue rifaximin 550 mg orally twice daily in patients with a history of two or more HE episodes in the past six months.
  • Consider spacing doses (e.g., once daily) only in cases of sustained remission, with close monitoring, and when cost is a significant concern.
  • No renal or hepatic dosing adjustment is needed for rifaximin. However, the fluid load from lactulose may require modification in patients undergoing continuous renal replacement therapy (CRRT).

Monitoring for Recurrence During Weaning

  • Neurologic Scales: Use the West Haven criteria or Conn score for routine assessment of overt HE.
  • Psychometric Tools: Where available, tools like the Inhibitory Control Test can be used to detect minimal HE.
  • Ammonia Levels: Avoid routine monitoring of ammonia levels, as they correlate poorly with clinical status during recovery.
  • Caregiver Input: Reports from caregivers about subtle changes in behavior, confusion, or the presence of asterixis should trigger an immediate dose reassessment.
Clinical Pearl Icon A shield with an exclamation mark, indicating a key clinical point. Clinical Pearl: Titrate to Stool Output, Not Catharsis +

The primary goal of lactulose therapy is to achieve 2–3 soft stools per day, not maximal catharsis. Over-aggressive dosing leads to dehydration, electrolyte disturbances (hypokalemia, hypernatremia), and patient discomfort, which can paradoxically worsen the clinical picture.

2. Conversion from Intravenous to Enteral/Oral Formulations

Transitioning from intravenous (IV) to enteral/oral therapy is a key step that reduces line-associated infection risks and supports early mobilization and nutrition.

Indications and Timing

  • Clinical Stability: The patient should be hemodynamically stable, off vasopressor support, and have an intact, functioning gastrointestinal tract.
  • Airway Protection: The patient must be able to protect their airway or have a secured enteral access device in place.

Enteral Access Devices

  • Short-term: Nasogastric (NG) or nasojejunal (NJ) tubes are suitable for short-term use.
  • Long-term: A percutaneous endoscopic gastrostomy (PEG) tube should be considered if enteral access is anticipated for more than four weeks.
  • Administration: Always check tube patency and placement before each medication administration.

Dose Equivalence and Bioavailability

  • Lactulose: The enteral dose is generally equivalent to the IV dose (1:1 ratio). However, monitor for increased GI side effects like bloating and cramping upon conversion.
  • Rifaximin: Rifaximin does not have an IV formulation. Maintain the standard oral twice-daily dosing schedule once the enteral route is established.
Editor’s Note Icon A clipboard with a pencil, indicating an editorial note or a gap in evidence. Editor’s Note: Evidence Gap +

Insufficient source material exists for detailed bioavailability data, comparative pharmacokinetic/pharmacodynamic studies, and device-specific administration protocols. A complete clinical guideline would ideally include data on absorption kinetics, medication stability in various feeding formulas, tube-feed compatibility, and stepwise conversion algorithms to ensure therapeutic equivalence.

3. Mitigating Post-ICU Syndrome (PICS)

Critically ill cirrhotic patients are at extremely high risk for PICS, which encompasses delirium, long-term cognitive decline, and functional impairment. Early rehabilitation and bundle-based care are essential to reduce these long-term deficits.

ABCDEF Bundle Components

The ABCDEF bundle is a proven, evidence-based framework for improving ICU patient outcomes:

ABCDEF Bundle for ICU Care A flowchart illustrating the six components of the ABCDEF bundle: A for Assess Pain, B for Both Awakening and Breathing Trials, C for Choice of Sedation, D for Delirium, E for Early Mobility, and F for Family Engagement. A Assess, Prevent & Manage Pain B Both Spontaneous Awakening/Breathing C Choice of Analgesia/Sedation D Delirium: Assess & Manage E Early Mobility & Exercise F Family Engagement
Figure 1: The ABCDEF Bundle. A multicomponent, evidence-based strategy to reduce delirium, improve pain management, and decrease long-term cognitive and functional impairment in ICU patients.

Cognitive and Functional Rehabilitation

  • Initiate occupational and physical therapy (OT/PT) consultations before ICU discharge to establish a baseline and plan for transition.
  • Set realistic mobility and Activities of Daily Living (ADL) goals with the patient and family, and monitor progress daily.

Identification and Referral

  • Screen high-risk patients, particularly those over age 65 or with prolonged mechanical ventilation (≥7 days).
  • Refer patients with identified deficits to neuropsychology or specialized post-ICU clinics for ongoing support after hospital discharge.
Editor’s Note Icon A clipboard with a pencil, indicating an editorial note or a gap in evidence. Editor’s Note: Implementation Details +

A comprehensive protocol would require more detailed implementation steps, including specific sedation regimens that minimize delirium (e.g., dexmedetomidine over benzodiazepines), standardized mobility checklists for daily goal setting, and metrics for tracking bundle compliance and its impact on patient outcomes.

4. Medication Reconciliation and Discharge Education

A pharmacist-led medication reconciliation process combined with targeted education at transitions of care is critical to reduce medication errors, prevent omissions, and empower patients and caregivers to detect early signs of HE recurrence.

Structured Reconciliation Process

  1. Verify: Compare the current inpatient regimen against the patient’s pre-admission medication list to identify discrepancies.
  2. Confirm: Ensure orders for lactulose and rifaximin are correct and clearly written. Actively discontinue any sedatives or analgesics with significant hepatic metabolism (e.g., benzodiazepines, opioids).
  3. Generate: Create an accurate and easy-to-understand outpatient medication list. Provide prescriptions with bridging supplies as needed to avoid gaps in therapy.

Patient and Caregiver Counseling

  • Signs of HE: Teach how to recognize early warning signs like confusion, lethargy, personality changes, and asterixis (hand flapping).
  • Therapy Goals: Reinforce the importance of achieving 2-3 soft bowel movements daily and explain how to monitor fluid and electrolyte status.
  • Adherence: Emphasize strict adherence to antibiotic regimens (rifaximin) and dietary recommendations.

Health Literacy–Tailored Materials

  • Use pictograms, simplified dosing schedules, and large-print materials.
  • Employ the teach-back method to confirm understanding of key concepts.
  • Provide clear crisis contact information and pathways for when to seek urgent medical attention.

Telehealth Follow-up

Schedule a telehealth follow-up call within 7 days of discharge to review medication adherence, check the patient’s stool diary, and screen for symptoms using a standardized checklist. This allows for early adjustment of the lactulose dose to maintain therapeutic goals and prevent dehydration.

Clinical Pearl Icon A shield with an exclamation mark, indicating a key clinical point. Clinical Pearl: The Power of a Checklist +

Implementing a standardized discharge checklist that includes medications, follow-up appointments, crisis contacts, and patient education confirmation has been shown to halve readmission rates for patients with hepatic encephalopathy.

5. Outpatient Follow-Up and Secondary Prevention

Early and structured outpatient engagement is crucial for identifying minimal HE, optimizing nutrition, and preventing readmission through reinforcement of adherence.

Scheduling Early Visits

  • Schedule the first follow-up visit (in-person or telehealth) within 7–14 days post-discharge.
  • Coordinate this visit with hepatology, nutrition, and clinical pharmacy services to provide comprehensive care.

Monitoring Minimal Hepatic Encephalopathy (MHE)

  • Psychometric Tests: Use validated tools like the Inhibitory Control Test or the paper-based Psychometric Hepatic Encephalopathy Score (PHES) battery.
  • Clinical Relevance: Identifying subtle cognitive deficits is critical, as MHE is a major predisposing factor for falls, motor vehicle accidents, and progression to overt HE.

Nutritional and Diet Strategies

  • Protein Intake: Target 1.2–1.5 g/kg of ideal body weight per day.
  • Energy Intake: Aim for 35–40 kcal/kg of ideal body weight per day.
  • Meal Plan: Encourage small, frequent meals and a late-night snack to prevent overnight catabolism. Consider branched-chain amino acid (BCAA) supplements for patients with protein intolerance.
Clinical Pearl Icon A shield with an exclamation mark, indicating a key clinical point. Clinical Pearl: Unmasking Minimal HE +

Early psychometric screening in the outpatient setting can unmask minimal HE in patients who appear clinically normal. This allows for timely therapy re-escalation, targeted patient education, and implementation of fall prevention strategies before a significant adverse event occurs.

6. Quality Metrics and Continuous Improvement

Systematically tracking process and outcome metrics is essential to inform protocol refinement, demonstrate the value of pharmacist-led interventions, and drive continuous quality improvement.

Readmission and Hospitalization Rates

  • Primary Outcome: The 30-day HE-related readmission rate is a key performance indicator.
  • Benchmarking: Compare institutional performance against published national averages to identify areas for improvement.

Patient-Reported Outcomes and Caregiver Satisfaction

  • Use validated quality-of-life (QoL) instruments and satisfaction surveys at follow-up visits.
  • Incorporate caregiver burden assessments to understand the full impact of the disease and its management on the family unit.

Protocol Audit and PDSA Cycles

  • Audit: Regularly review adherence to key processes, such as discharge checklist completion, timely follow-up scheduling, and delivery of patient education.
  • Improve: Use Plan–Do–Study–Act (PDSA) cycles to implement changes based on barrier analysis and feedback from patients, caregivers, and clinicians.
Clinical Pearl Icon A shield with an exclamation mark, indicating a key clinical point. Clinical Pearl: Pharmacist Impact +

Data consistently shows that higher rates of pharmacist-led discharge medication reviews and counseling sessions correlate directly with fewer HE-related readmissions and improved medication adherence at 30 and 90 days.

References

  1. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by AASLD and EASL. Hepatology. 2014;60(2):715–735.
  2. Fallahzadeh MA, Rahimi RS. Hepatic encephalopathy: current and emerging treatment modalities. Clin Gastroenterol Hepatol. 2022;20(S9–S19):S9–S19.
  3. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–1081.
  4. Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for nonsystemic GI infections. Expert Rev Anti Infect Ther. 2005;3(2):201–211.
  5. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification. Hepatology. 2002;35(3):716–721.
  6. Tapper EB, Parikh ND. Inadequate practices for HE management in hospitalized patients: importance of medication reconciliation and patient education. Hepatol Commun. 2022;6(9):xxx–xxx.
  7. Williams J, Jesudian A. Medication reconciliation in HE management. HCPLive. 2023.
  8. Bajaj JS, Hafeezullah M, Franco J, et al. Inhibitory control test for diagnosis of minimal HE. Gastroenterology. 2008;135(5):1591–1600.
  9. Roman E, Córdoba J, Torrens M, et al. Minimal HE is associated with falls. Am J Gastroenterol. 2011;106(3):476–482.
  10. Amodio P, Bemeur C, Butterworth R, et al. Nutritional management of HE in cirrhosis: ISHEN guidelines. Hepatology. 2013;58(1):325–336.
  11. Poordad FF. The burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25(Suppl 1):3–9.
  12. Jesudian A, Williams J. Discharge planning and transition of care in HE. HCPLive. 2023.
Previous Topic
Back to Lesson
Next Lesson